Table VII.
Multivariate analysis of overall survival in PTCL-NOS.
| Overall survival | ||
|---|---|---|
| Factor | OR (95% CI) | P-value |
| LDH | ||
| Upper limit of normal vs. normal | 0.649 (0.253–1.665) | 0.368 |
| B2M | ||
| Upper limit of normal vs. normal | 0.633 (0.213–1.879) | 0.410 |
| IPI | ||
| 0–2 vs. 3–5 | 1.012 (0.300–3.411) | 0.985 |
| Ki-67 | ||
| >31% vs. ≤30% | 0.476 (0.175–1.294) | 0.146 |
| Clinical staging | ||
| III–IV vs. I–II | 0.444 (0.119–1.653) | 0.226 |
| Presence of B symptoms | ||
| Present vs. absent | 0.468 (0.185–1.185) | 0.109 |
| Marrow involvement | ||
| Present vs. absent | 0.640 (0.274–1.495) | 0.303 |
| Sex | ||
| Female vs. male | 0.418 (0.162–1.079) | 0.072 |
| Age | ||
| >60 vs. ≤60 | 0.973 (0.418–2.265) | 0.949 |
| Expression of HDAC2 | ||
| Low expression vs. high expression | 2.990 (1.102–8.112) | 0.032a |
a
P<0.05. PTCL-NOS, PTCL not otherwise specified; OR, odds ratio; CI, confidence interval; LDH, lactate dehydrogenase; B2M, β2 microglobulin; IPI, international prognostic index; HDAC2, histone deacetylase 2.